The active medication arm experienced statistically significant advantages in two objective clinical outcomes: weight and PPG. There were no significant differences for A1C or insulin requirements.Table 1End of the trial measures by treatment groupThe pramlintide arm had a statistically significant advantage for all PRO measures except hypoglycemia prevention and abs